Genedata, a Danaher company, has entered into a partnership with mAbxience, a global contract development and manufacturing organization, to deploy the Genedata Bioprocess enterprise platform across mAbxience’s operations. The platform will structure and harmonize bioprocess development data, enabling faster development cycles and stronger data governance.
The partnership expands Danaher’s life‑sciences portfolio by adding a new customer to its Genedata software suite. As mAbxience scales its biologics manufacturing capabilities, the deal is expected to generate recurring revenue from licensing and support services. The collaboration also demonstrates how Danaher leverages its 2024 acquisition of Genedata to deliver integrated solutions to CDMOs.
mAbxience, majority‑owned by the Fresenius Kabi group, specializes in biosimilars for oncology, hematology, osteoporosis, and pediatrics. "With our growing biosimilars portfolio and increasing complexity in bioprocess development, we needed a single, integrated platform that connects and analyzes all data across upstream, downstream, cell line, formulation, and analytical development," said Ivan Sánchez de Melo, R&D Director at mAbxience. "Genedata Bioprocess, operated in the Genedata Cloud, automates our processes and ensures full data integrity and traceability across all groups. This foundational system allows us to scale efficiently and prepare for the next step—process modeling—while meeting global demand for high‑quality biologics.",
"We are delighted to welcome mAbxience to the Genedata community, and to further expand our footprint in the CDMO industry," said Othmar Pfannes, President of Genedata. "By centralizing all data in one platform, mAbxience is taking a major step toward automation and data integrity, increasing its AI maturity and readiness. This investment ensures scalability, compliance, and innovation for biosimilar manufacturing. We will continue to invest in the Genedata platform to address the needs of a rapidly growing CDMO industry.",
The partnership aligns with Danaher’s Danaher Business System, which emphasizes operational excellence and data‑driven efficiency. By integrating Genedata’s platform, mAbxience can accelerate bioprocess development, improve data governance, and position itself to meet the growing demand for high‑quality biologics.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.